NIAID's Carl Dieffenbach, Ph.D., joins Anne Rancourt to discuss some key takeaways from the 10th International AIDS Society Conference on HIV Science.
Advocates say the price is a step in the right direction. But does it go far enough?
The chance of HIV rebounding after starting and maintaining antiretroviral therapy lies close to 1% per year in certain groups living with HIV, according to a study published in The Lancet HIV.
From 2008 through 2014, rates of entering HIV care and starting treatment rose significantly among gay and bisexual men in a 20-city study.
Chronic inflammation seen in people living with HIV is related to how much damage HIV causes before starting treatment, rather than HIV activity while taking meds, according to a new study.
Starting HIV treatment soon after diagnosis may reduce the risk of developing HIV-related cancer by 74%, according to a recent study.
Tivicay is a mainstay of HIV treatment and the focus of simplified treatment studies due to its power and high drug resistance barrier; however, side effects concerns have recently been raised.
Starting meds quickly after HIV infection can preserve immune system functioning, reduce inflammation and more. And studying the effects of such treatment could also bring us closer to a functional cure of HIV.
In areas with easy access to HIV medications, people have a wealth of regimens to choose from that work well and are unlikely to cause serious side effects. In fact, sometimes, it can feel like there are too many choices.
"Every five years we have more than doubled the number of people on life-saving treatment," said Michel Sidibé of UNAIDS. "We need to do it just one more time to break the AIDS epidemic and keep it from rebounding."